home / stock / rfl / rfl news

RFL News and Press, Rafael Holdings Inc. Class B From 12/02/19

Stock Information
Company Name: Rafael Holdings Inc. Class B
Stock Symbol: RFL
Market: NYSE
Website: rafaelholdings.com
Menu
RFL RFL Quote RFL Short RFL News RFL Articles RFL Message Board
Get RFL Alerts

News, Short Squeeze, Breakout and More Instantly...
RFL - Rafael Pharmaceuticals Announces Expansion of Phase 2 Trial of CPI-613® (devimistat) for Patients with Relapsed or Refractory Burkitt's Lymphoma/Leukemia to Massachusetts General Hospital in Boston

Cranbury, N.J., Dec. 02, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the expansion of its Phase 2 clinical trial of CPI-613® (devi...
RFL - Rafael Holdings to Begin Trading on the NYSE

NEWARK, N.J. , Nov. 18, 2019 /PRNewswire/ --   Rafael Holdings, Inc., (NYSE American: RFL), announced today that it has been approved for listing on the New York Stock Exchange (NYSE).  The Company anticipates that its Class B common stock will begin trading on the NYS...

RFL - Tracking Kahn Brothers' Portfolio - Q3 2019 Update

This article is part of a series that provides an ongoing analysis of the changes made to Kahn Brothers' 13F stock portfolio on a quarterly basis. It is based on Kahn Brothers' regulatory 13F Form filed on 11/05/2019. Please visit our Tracking Kahn Brothers Portfolio series to get an idea ...

RFL - Rafael Pharmaceuticals Joins the Pancreatic Cancer Action Network's Scientific & Medical Affairs Industry Membership

Cranbury, NJ, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has joined the Scientific & Medical Affairs Industry Memb...
RFL - Rafael Pharmaceuticals Appoints Chief Medical Officer, José Octávio Costa Filho, M.D.

Cranbury, NJ, Oct. 30, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that José Octávio Costa Filho, M.D., will join the company ...

RFL - Rafael Pharmaceuticals Reaches Milestone of 25 Active Sites for Pivotal Phase 3 Trial (ARMADA 2000) of CPI-613® (devimistat) in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

Cranbury, NJ, Oct. 28, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced the milestone activation of 25 sites for its pivotal Phase 3 clinica...

RFL - Rafael Pharmaceuticals Announces Expansion into South Korea of Pivotal Phase 3 Trial of CPI-613® (devimistat) in Patients with Metastatic Pancreatic Cancer

Cranbury, NJ, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that the Phase 3 clinical trial ( PANC 003) of CPI-613® (devim...
RFL - Rafael Pharmaceuticals Enters into Collaboration with the National Institutes of Health (NIH) to Test CPI-613® (devimistat) in Cytokine Independent (Acute) HTLV-1 Associated Adult T-cell Leukemia/Lymphoma

Cranbury, NJ, Oct. 17, 2019 (GLOBE NEWSWIRE) --   Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, announced today that it has entered into a collaboration with the National C...

RFL - Rafael Pharmaceuticals Congratulates Scientific Advisory Board Member Gregg L. Semenza For Receiving 2019 Nobel Prize in Medicine

Cranbury NJ, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, congratulates Gregg L. Semenza, M.D., Ph.D., scientific advisory board member at Raf...

RFL - Rafael Pharmaceuticals Reaches Milestone of 100 Patients Enrolled in Pivotal Phase 3 Trial (AVENGER 500) of CPI-613®? (devimistat) for Patients with Metastatic Pancreatic Cancer

Cranbury, NJ, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Rafael Pharmaceuticals, Inc. (“Rafael” or the “Company”), a leader in the growing field of cancer metabolism-based therapeutics, today announced that it has enrolled 100 patients in its pivotal Phase 3 clinical tr...
Previous 10 Next 10